Sign up to SCR Digest, our FREE weekly newsletter, and receive our Notes emailed directly to you.
Email Address *
First Name
Mailing Lists *


ABDC: Alcentra Begins Its Comeback

05/08/2018
By Lisa Thompson

NASDAQ:ABDC

After substantial write downs in 2017, new management has set Alcentra (NASDAQ:ABDC) on a new course and its first quarter results have shown the portfolio is back on track. Sequentially NAV has grown again. Net asset value (NAV) was $157.2 million, or $11.22 per share as of March 31, 2018 versus $11.06 per share, on December 31, 2017. For the first quarter of 2018, the company reported total investment income of $8.2 million versus $9.2 million last year, a decline of 12%. Adjusted and net investment income was $3.8 million, or $0.27 per share versus $4.6 million and $0.34 per share last year.

ABDC shares provide 11.3% dividend and trade at a 43% discount to the company’s $11.22 NAV/ share.

Of the 28 portfolio companies, there were two write ups and two write downs this quarter, overall the portfolio value remained relatively flat. There was a realized plus unrealized net decrease in the portfolio of $237,000.

During Q1 the company received proceeds from repayments and amortizations on investments of $47.6 million and invested $29.6 million, including investments in one new portfolio company, two add on investments, six broadly syndicated loans, and three rated CLO debt securities.

Investments during the quarter were the following:

• BayMark Health Services - $7.0 million in L+8.25% 2nd lien secured debt

• Healthcare Associates of Texas (HCAT) - $2.9 million of the delayed draw commitment
• Cirrus Medical Staffing - $1.4 million of the delayed draw commitment

• FeeCo - $1.8 million in L+8.5% 2nd lien secured debt
West Corporation - $2.0 million in L+3.5% 1st lien secured debt

• Weight Watchers International - $2.0 million in L+4.75% 1st lien secured debt

• Lumileds - $2.0 million in L+3.5% 1st lien secured debt

• Asurion - $3.1 million in L+6.0% 2nd lien secured debt

• Red Ventures LLC - $2.0 million in L+4.0% 1st lien secured debt

• BlueMountain CLO 2016-3 Ltd. - Invested $2.0 million with a yield of L+6.85%
• Goldentree Loan Management US Clo 2 Ltd. - Invested $1.9 million with a yield of L+4.7%
• OZLM Funding IV Ltd. - Invested $1.4 million with a yield of L+6.3%

Repayments, loan dispositions, and amortizations on investments during the quarter totaled $47.6 million, comprised of: sale of Stancor, Inc. and IGT and the repayment of debt from Metal Powder Products and NextCare Holdings, Inc.

READ THE FULL RESEARCH REPORT HERE.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.
 
User ID:
Password:
Remember my ID: